Author

Peter D. Byeff

Observed names: P Byeff, P. D. Byeff, Peter Byeff

Institution: The Hospital of Central Connecticut

Observed institutions: University College Dublin, Atrium Health Wake Forest Baptist, University of Connecticut, Mater Misericordiae University Hospital, New Britain General Hospital, Cancer Trials Ireland, The Hospital of Central Connecticut, Wake Forest University, UConn Health, Columbia University

OpenAlex ID: A5062364489

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

2017 · Miguel Martin, Frankie A Holmes, et al. · The Lancet Oncology · 587

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

2019 · Paul G Richardson, Albert Oriol, et al. · The Lancet Oncology · 384

Mycobacterium haemophilum Infection in Immunocompromised Patients: Case Report and Review of the Literature

1991 · M. Kristjansson, V. M. Bieluch, et al. · Clinical Infectious Diseases · 76

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial

2019 · Kathleen M Mullane, Vicki A Morrison, et al. · The Lancet Infectious Diseases · 37

Phenotypic heterogeneity of human T‐cell malignancies: Demonstration by monoclonal antibodies and cytochemical markers

1982 · Daniel M. Knowles, James P. Halper, et al. · American Journal of Hematology · 20

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

2020 · Katja Weisel, Meletios Dimopoulos, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 13

Meningococcal Arthritis

1976 · Peter D. Byeff · JAMA · 9

Meningococcal arthritis

1976 · P. D. Byeff · JAMA · 8

Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimismm Study

2018 · Katja Weisel, Meletios A Dimopoulos, et al. · Blood · 1

Fibrinogen New Britain

1994 · C. D. Webb, R. R. Hantgan, et al. · Blood Coagulation & Fibrinolysis · 1

Bleeding Complications in Patients with Cancer and COVID 19- Analysis from the COVID 19and Cancer Consortium (CCC19) Registry

2021 · Surbhi Shah, Shuchi Gulati, et al. · Blood

Works count: 12

Citation count: 1,136

H-index: 8

I10-index: 6